MetaCap

Neuropace (NPCE) vs OraSure Technologies (OSUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OraSure Technologies (OSUR) has outperformed Neuropace (NPCE) over the past year, gaining 52.4% versus a loss of 44.6%. Over five years, NPCE leads with a -32.8% price change compared with -63.7% for OSUR. Neuropace is the larger company by market cap ($273.9 million vs $238.9 million), about 1.1 times the size.

Neuropace converts more of its revenue into profit, with a net margin of -21.5% versus -59.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NPCE-44.60%OSUR+52.42%
+106%+25%-55%
Nov 21, 20251 yearNov 20, 2026
NPCE-32.91%OSUR-64.77%
+62%-17%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NPCE versus OSUR key metrics
MetricNPCEOSUR
Share price$7.95$3.46
Market cap$273.89M$238.90M
1-day change-2.33%-4.16%
YTD return-48.51%+42.98%
1-year return-44.60%+52.42%
5-year return-32.80%-63.69%
EPS (TTM)$-0.56$-0.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$99.99M$115.02M
Revenue growth (YoY)+25.13%-38.10%
Net income (latest FY)$-21.46M$-68.73M
Gross margin77.23%41.90%
Operating margin-16.34%-62.57%
Net margin-21.47%-59.76%
52-week high$19.60$4.58
52-week low$5.46$2.28
Distance from 52-week high-59.44%-24.45%
Analyst consensusbuybuy
Avg. price target upside+53.71%+58.96%
Average volume270.76K571.50K
Shares outstanding34.45M69.05M
Employees216500
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OSUR has outperformed NPCE by 97.0 percentage points over the past year.
  • Neuropace is more profitable, keeping -21.5 cents of every revenue dollar as net income versus -59.8 cents for OraSure Technologies.
  • Neuropace grew revenue faster in its latest fiscal year (+25.13% vs -38.10%).

About Neuropace

NPCE stock →

NeuroPace, Inc. operates as a medical device company in the United States.

Health Care · Medical/Dental Instruments · 216 employees

About OraSure Technologies

OSUR stock →

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Health Care · Medical/Dental Instruments · 500 employees

NPCE vs OSUR FAQ

Which is bigger, Neuropace or OraSure Technologies?

Neuropace (NPCE) is larger, with a market capitalization of $273.89M compared with $238.90M for OraSure Technologies (OSUR).

Which stock has performed better over the past year, NPCE or OSUR?

OSUR returned +52.42% over the past 12 months, compared with -44.60% for NPCE (price return, excluding dividends). Past performance does not predict future results.

Are Neuropace and OraSure Technologies in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons